BridgeBio Pharma retains a majority stake in spinoff Eidos, which has raised $91m in funding in just over a year.
Eidos Therapeutics, a US-based US-based biopharmaceutical spinoff of genetic disease drug developer BridgeBio Pharma, has filed for a $115m initial public offering on the Nasdaq Global Market.
Eidos is developing therapeutics that will treat diseases by stabilising a protein known as transthyretin (TTR), and its lead product candidate is a small molecule called AG10.
Most of the IPO proceeds will fund a phase 2 clinical trial for AG10 in a cardiac condition known as transthyretin amyloid cardiomyopathy, and a…
